BASF's Strong Quarter Comes With an Evonik Asterisk

A 15% EBITDA jump, a weak Ag print, and a capital-discipline story that now includes a possible European chemical merger.

BAS.DE · Earnings Call · 2026-10-28

The Evonik Elephant in the Room

BASF did not bury the lede. Before CFO Dirk Elvermann walked through the €1.6bn in EBITDA before special items, up 15% year over year, CEO Markus Kamieth addressed the possible combination with Evonik. That is a change in tone from July, when M&A was framed as observing industry consolidation from the sidelines. This time he called a combination a logical step and said “The timing is right, not only for BASF, but also for the chemical industry.” — Markus Kamieth, CEO or Executive Board Member · 2026-10-28 The caveat was equally clear: “Acquisitions are a could do, not a must do in our strategy.” — Markus Kamieth, CEO or Executive Board Member · 2026-10-28 For a company that has spent years selling businesses, buying back stock and deleveraging, an Evonik approach is a strategic pivot, not a quarterly fluctuation. It also explains why Winning Way strategy and capital allocation framework dominated the prepared remarks. The market may have to price a larger, more complex BASF — or no deal at all.

A potential combination with Evonik would be a logical and meaningful step in this direction. The timing is right, not only for BASF, but also for the chemical industry. Consolidation in Europe is underway and BASF is well positioned to drive and shape it.
Markus Kamieth, CEO or Executive Board Member · 2026-10-28

A Tale of Two Portfolios

Strip out Evonik and Q3 was a core-business story. All four core segments raised prices, volumes grew, and the Zhanjiang ramp plus a local-for-local footprint helped offset a still-difficult European industrial backdrop. That is the good news. The bad news sits in Agricultural Solutions, where sales fell almost 20% to €1.4bn. Lower volumes, competitive pressure in South America and an ERP migration that pulled sales into Q2 all conspired against the segment. Elvermann was blunt: “The biggest downside driver was indeed volumes. Part was explained by this preponement due to the ERP migration.” — Dirk Elvermann, CFO or Finance Executive · 2026-10-28 Management still expects the usual seasonal strengthening in Q4, but the Ag IPO — targeted for mid-2027 — is now the key value catalyst to watch. The same quarter also showed the Zhanjiang site running at a slightly negative EBITDA, with full-year guidance around minus €100m. That is not a disaster, but it punctures the idea that China is a near-term profit engine. Kamieth was candid: “Q3, we came out slightly negative. We stick to our overall year guidance where we said we will probably end up in the area of minus EUR 100 million roughly EBITDA on the Zhanjiang site all in.” — Markus Kamieth, CEO or Executive Board Member · 2026-10-28 The operational ramp is going well; the market is not cooperating on margins. That is a common chemical-industry tension, but it matters more when BASF is asking investors to pay for a capital-discipline story.

Energy, Working Capital, and the Q4 Warning

The Q3 beat had a helpful tailwind: price increases after the Middle East conflict tightened upstream markets and lifted feedstock prices. That tailwind is fading into a different Q4. Kamieth warned “Q4 could be a quarter where lower demand hits higher energy costs.” — Markus Kamieth, CEO or Executive Board Member · 2026-10-28 Energy remains roughly 5% of total costs, and gas is still the biggest carrier. BASF’s LNG contracts and hedging help, but they do not make the company immune to the global energy cycle. The cash flow picture is messy. Free cash flow was minus €1bn for the first nine months as working capital absorbed €4.1bn, mostly receivables and inventory values. Management expects a strong Q4 collection, and the balance sheet work is real: net debt down 20% year over year, equity ratio up to 47.2%, and CapEx cut to €2.8–2.9bn. Kamieth framed the lower spending as structural: “This is really now bringing BASF into a capital discipline fitness regime, and we think we can sustain that level for quite some time.” — Markus Kamieth, CEO or Executive Board Member · 2026-10-28 Keywords like cash inflow and payments made for property tell the story: portfolio proceeds from Coatings, Harbour Energy and Stahl are funding deleveraging and buybacks, not a new capacity binge. Europe policy is the other undercurrent. Kamieth argued that the EU’s existing trade defense mechanism should be used more sharply before new instruments are invented. That is a balanced, industry-friendly line, but it also signals how defensive the European chemical backdrop remains.

What Actually Changed

The quarter is strong but not clean. BASF raised the low end of its EBITDA guidance to €7.4–7.8bn and narrowed the range, yet management sounded cautious on Q4 and kept free cash flow guidance unchanged at €1.5–2.3bn. The mid-cycle language is carefully hedged: out of the trough, but not at normalized margins. Prior calls repeatedly described weak demand and oversupply; this one points to slightly better leading indicators, but from a low base. The Evonik option adds a strategic wildcard on top of an Ag recovery story that has not yet arrived. What changed is not the cycle — it is the capital allocation posture. BASF is trying to convince investors it can be a leaner, more disciplined chemical company, even while carrying a weak Ag business and a Chinese site that is still losing money. If core earnings keep rising and Evonik is pursued without breaking the €12bn distribution promise, the re-rating case is credible. If Q4 energy costs bite and Ag stays soft, the market will treat the Evonik headline as a distraction from a still-cyclical earnings base.